Presentation TCT 2016 Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives Presenter: Aaron V. Kaplan, Rachel Neubrander, Brian K. Whisenant November 01, 2016
Presentation TCT 2016 Editorial Comment: Current Guidelines, Device, and Anticoagulation Strategies Presenter: Bagrat Alekyan, Grzegorz L. Kaluza, Thomas D. Stuckey November 01, 2016
Presentation TCT 2016 Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI Presenter: David P. Faxon, C. Michael Gibson, Deepak L. Bhatt November 01, 2016
Presentation TCT 2016 General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI Presenter: David P. Faxon, C. Michael Gibson, Dominick J. Angiolillo November 01, 2016
Presentation TCT 2016 European Guidelines on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI Presenter: David P. Faxon, C. Michael Gibson, Davide Capodanno November 01, 2016
Presentation TCT 2016 Antiplatelet Therapy in Patients Who Need Anticoagulation: Current Guidelines, Ongoing Studies Presenter: George D. Dangas, Debabrata Mukherjee, C. Michael Gibson November 01, 2016
Presentation TCT 2016 Flash Debate: Counterpoint 4D-CT Leaflet Imaging Findings Will Help to Direct Anticoagulation Therapy! Presenter: Raj Makkar, Lars Sondergaard October 31, 2016
Presentation TCT 2016 Trial #2 - The Essentials of ... the MATRIX Trial Access Site and Anticoagulation Type (And Infusion Duration) in ACS Presenter: Sunil V. Rao, Harvey D. White, Salvatore Brugaletta October 31, 2016
Presentation TCT 2016 TCT 79: Course of Early Subclinical Leaflet Thrombosis After Transcatheter Aortic Valve Replacement With or Without Oral Anticoagulation Presenter: John M. Lasala, Philippe Pibarot, Jürgen Rothe October 31, 2016
Presentation TCT 2016 TCT 54: LEADERS FREE OAC: Biolimus A9 Coated vs Bare Metal Stents in Patients Requiring Oral Anticoagulation. A Prespecified Subgroup Analysis of the LEADERS FREE Trial Presenter: Neal S. Kleiman, David F. Kong, Didier Carrié October 31, 2016
Presentation TCT 2016 Debate #1: Should Low Bleeding Risk Patients With Atrial Fibrillation Be Offered LAA Closure? No Chronic Anticoagulation Should be Offered First Presenter: David R. Holmes Jr., Josep Rodés-Cabau, Stefan C. Bertog October 30, 2016
News Conference News TCT 2016 LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years Yael L. Maxwell October 30, 2016
Presentation TCT 2016 Reversal of Chronic Anticoagulation: When, What, and How Effective? Presenter: Paul A. Gurbel, James A. Reiffel October 30, 2016
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for October 2016 Caitlin E. Cox October 29, 2016
News Daily News Short Bouts of Atrial Tachyarrhythmia Do Not Worsen Prognosis, Study Suggests Todd Neale October 19, 2016
News Daily News Oral Anticoagulation Use Common in PCI Patients, With Triple Therapy the Norm at Discharge Todd Neale October 18, 2016
News Daily News A-fib Screening With Smartphone-Based ECG Feasible, but Clinical Impact Unclear Todd Neale October 13, 2016
News Daily News FDA: ROCKET AF Results Not Affected by Faulty INR Testing in Warfarin Arm Michael O'Riordan October 11, 2016
News Daily News More NOAC Comparisons See Higher Bleeding Risk With Rivaroxaban: Is the ‘Writing on the Wall’? Shelley Wood October 07, 2016
News Daily News Addition of Biomarkers May Fine Tune Risk Stratification in Atrial Fibrillation Michael O'Riordan October 07, 2016